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RESEARCH ARTICLE
Disposable screen printed 
sensor for the electrochemical detection 
of methamphetamine in undiluted saliva
Carrie‑Ann Bartlett, Sarah Taylor, Carlos Fernandez, Ceri Wanklyn, Daniel Burton, Emma Enston, 
Aleksandra Raniczkowska, Murdo Black and Lindy Murphy*
Abstract 
Background: Methamphetamine has an adverse effect on the ability to drive safely. Police need to quickly screen 
potentially impaired drivers therefore a rapid disposable test for methamphetamine is highly desirable. This is the first 
proof‑of‑concept report of a disposable electrochemical test for methamphetamine in undiluted saliva.
Results: A screen printed carbon electrode is used for the N,N′‑(1,4‑phenylene)‑dibenzenesulfonamide mediated 
detection of methamphetamine in saliva buffer and saliva. The oxidized mediator reacts with methamphetamine to 
give an electrochemically active adduct which can undergo electrochemical reduction. Galvanostatic oxidation in 
combination with a double square wave reduction technique resulted in detection of methamphetamine in undi‑
luted saliva with a response time of 55 s and lower detection limit of 400 ng/mL.
Conclusions: Using a double square wave voltammetry technique, rapid detection of methamphetamine in undi‑
luted saliva can be achieved, however there is significant donor variation in response and the detection limit is signifi‑
cantly higher than desired. Further optimization of the assay and sensor format is required to improve the detection 
limit and reduce donor effects.
Keywords: Square wave voltammetry, SWV, Galvanostatic oxidation, Screen printed electrode, Mediator, 
Methamphetamine, Saliva, Detection
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Background
Two thirds of US trauma centre admissions are due 
to motor vehicle accidents with almost 60  % of such 
patients testing positive for drugs or alcohol [1]. Canna-
bis, cocaine and methamphetamine are the drugs most 
frequently detected in drivers randomly stopped for 
roadside drug screening [2–5]. In Norway prior to the 
year 2000 there was almost no methamphetamine on the 
Norwegian market. There was a steady increase in meth-
amphetamine usage till 2010 where it appeared to have 
stabilized. The data for this study was confirmed by test-
ing venous blood of convicted motorists, customs sei-
zures and wastewater analysis [6]. A US survey, using a 
questionnaire which annually monitored adolescent drug 
use, showed a gradual decline in methamphetamine use 
from 3.7  % in 1981 (peak year) to 1.2  % in 2008 [7]. A 
recent study showed conflicting trends when comparing 
the questionnaire survey approach and wastewater analy-
sis. Over the period 2010–2013 the population survey 
showed a slight decline in methamphetamine use while 
wastewater analysis showed a doubling of methampheta-
mine usage [8].
Methamphetamine remains a significant public health 
concern with known neurotoxic and neurocognitive 
effects to the user [9]. It is frequently abused as a rec-
reational drug due to its stimulant and euphoric effects. 
The physiological and psychological side effects of 
methamphetamine include confusion, paranoia, depres-
sion, nausea and blurred vision. Driving a vehicle while 
under the influence of methamphetamine is thus clearly 
undesirable.
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Roadside screening for methamphetamine in oral 
fluid has a number of requirements: it needs to be fast, 
ideally 15–30  s, i.e. ideally the same speed as a breath 
alcohol test; it must be very sensitive, ideally <10 ng/mL 
(25  ng/mL was used as the cut-off concentration in the 
European DRUID [Driving under the influence of Drugs, 
Alcohol, and Medicines] project [5]); and it should be 
non-invasive, difficult to tamper with and be portable. 
The currently available drug screening products require 
a minimum of 5–10  min for a test [10]. Test time and 
cost are restricting the roadside drug screening market to 
<10 % the volume of the alcohol screening market.
Oral fluid which contains saliva and other liquid sub-
stances present in the oral cavity are of great interest 
for roadside drug screening. Although this fluid is easy 
to collect there is considerable inter-sample variability 
in the fluid matrix that generates issues when develop-
ing a testing methodology [11]. Dilution of the sample 
can reduce the donor variability, however this dilutes 
the drug of interest and therefore requires the device to 
have greater sensitivity. The current devices on the mar-
ket are primarily lateral flow immunodiagnostic tests, 
where the presence or absence of a coloured bar can be 
read either visually or in a meter in response to the drug 
of interest; these were used in the DRUID project. The 
response times are typically several minutes. The clini-
cal sensitivity of these devices in saliva can be relatively 
poor at 16–75 % although clinical specificity can be close 
to 100 % [12].
There are only a few reports of the electrochemical 
sensing of amphetamines, and there are no reports of the 
determination of amphetamines in undiluted saliva using 
disposable electrochemical sensors. Electrochemical sens-
ing of methamphetamine by direct oxidation has been 
reported at a pretreated pencil graphite electrode [LOD 
50  nM (7.5  ng/mL) in aqueous solution, response time 
>10 min] [13], at a self-assembled boron-doped diamond 
electrode [LOD 50  nM (7.5  ng/mL) in aqueous solution, 
response time not given] [14], and in alkaline solution 
using a gold nanoparticle-multiwalled carbon nanotube 
modified screen printed electrode [LOD 0.3 nM (0.05 ng/
mL), response time not given] [15]. The indirect electro-
chemical detection of amphetamine in saliva has been 
reported using 1,2-naphthoquinone-4-sulfonate at an edge 
plane pyrolytic graphite electrode [LOD 41  μM (6.2  μg/
mL) in aqueous solution, response time not given] [16].
This paper reports a mediated screen printed car-
bon electrode for the detection of methamphetamine in 
undiluted saliva using substituted N,N′-(1,4-phenylene)-
dibenzenesulfonamide mediator. Screen printed elec-
trodes are well established as cheap and disposable single 
use sensors which can be manufactured with high repro-
ducibility [17].
The sensor is optimized for speed of response and for 
response in undiluted saliva.
Results and discussion
Initial mediator screen
The mechanism of reaction between oxidized N,N′-(1,4-
phenylene)-dibenzenesulfonamide and primary and 
secondary amines has been described by Adams and 
Schowalter [18]. The mechanism is shown schemati-
cally in Fig.  1. The oxidized form of the mediator (II) 
reacts with secondary amines such as methamphetamine 
(MAMP) by 1,4-addition resulting in the reduced form 
of the MAMP-mediator adduct (III). Electron exchange 
between (III) and a further molecule of (II) results in 
the oxidized form of the adduct (IV) which can undergo 
reduction at the electrode at the appropriate reduction 
potential i.e. it can give rise to a new reduction peak in 
addition to the reduction peak for unreacted oxidized 
mediator, (II).
With primary amines such as amphetamine (AMP), 
1,2-addition can take place, resulting in elimination of the 
two benenesulfonamide groups from the mediator and 
formation of an AMP-mediator adduct. This adduct can 
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Fig. 1 Reaction of N,N′‑(1,4‑phenylene)‑dibenzenesulfonamide with methamphetamine (MAMP)
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also undergo oxidation via II and subsequently undergo 
electrochemical reduction.
An initial mediator screen was performed 
with several substituted N,N′-(1,4-phenylene)-
dibenzenesulfonamide compounds, described in 
Additional file  1. The mediators were screened for 
electrochemical response using differential pulse 
voltammetry (DPV) and reaction with MAMP. The 
sensors used were of the format shown in Fig. 2a, con-
sisting of a two electrode system of carbon working 
electrode and Ag/AgCl combined counter/reference 
electrode. The preferred mediator was OX1006 (N,N′-
(2-nitro-1,4-phenylene)dibenzenesulfonamide) on the 
basis of giving a large, clearly defined peak response 
to MAMP without adsorption of the parent media-
tor to the electrode. At pH 10.8, the mediator is fully 
deprotonated [pKas 6.05 and 8.00 (25 °C)] and soluble 
at 1 mg/mL, and this pH was used for the development 
of the sensor.
The cyclic voltammetry of OX1006 with MAMP is 
shown in Fig.  3. In the absence of MAMP, there is a 
single oxidation peak at +0.38 V and negligible reduc-
tion peak. In the presence of MAMP, two new peaks 
are present at +0.15 V and −0.046 V, and a new reduc-
tion peak is present at −0.088 V. In addition, the parent 
mediator peak height at +0.38 V is increased by 29 and 
47 % in the presence of 25 and 50 μg/mL MAMP. The 
increase in the parent peak height and the new peaks 
are due to the oxidation/reduction of the mediator-
MAMP adduct.
Optimization of electrochemical procedure with dried 
reagent
It was desired that the mediator and buffer solution be 
dried down in some way on the sensor. Deposition of 
mediator solution directly onto the sensor requires tight 
control of the volume and position of the dispensed rea-
gent. Therefore an alternative technique was used com-
prising a porous overlayer onto which mediator was dried 
and which is then secured over the sensor. On applica-
tion of sample, the mediator dissolves and diffuses to the 
working electrode where it can be oxidized, react with 
MAMP and produce a reduction response to MAMP. 
Sensors with overlayer applied are shown in Fig. 2b.
Galvanostatic oxidation of OX1006 was investigated 
in combination with the overlayer. The advantage of gal-
vanostatic oxidation compared to potentiostatic oxida-
tion is that the amount of oxidized mediator should be 
relatively independent of the concentration of mediator 
which has dissolved off the overlayer and reached the 
electrode surface, provided there is sufficient mediator. A 
Fig. 2 Screen printed electrodes a without and b with overlayer. The sensor comprises a circular carbon working electrode (2 mm diameter) and 
outer Ag/AgCl counter/reference electrode
Fig. 3 Cyclic voltammetry of OX1006 in the absence and presence of 
MAMP. The MAMP concentration was 0, 25 or 50 μg/mL MAMP (solid 
line, dotted line and dashed lines) in 0.1 M sodium carbonate buffer 
(pH 10.4), 0.2 M NaCl. 15 μL of solution was pipetted onto the sensor. 
The scan rate was 50 mV/s
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potential disadvantage of galvanostatic oxidation is that 
if there is insufficient mediator, other species present will 
be oxidized, resulting in a large increase in working elec-
trode potential.
There are very few reported examples of galvanostatic 
oxidation to generate reactant, and these examples are 
for electrochemical titrations using separate generator-
collector electrodes [19, 20]. For example, Tomcik et  al. 
[21] have reported the galvanostatic generation of hypo-
bromite at an interdigitated microelectrode array, for 
end-point titration of the drugs Antabus and Celaskon. 
In our application, the working electrode is used to both 
generate the reactant (oxidized mediator) and detect the 
mediator-MAMP adduct.
The shift in working electrode potential during gal-
vanostatic oxidation is shown in Fig. 4, for sensors with 
mediator in the overlayer and using a saliva sample. 
A 10  s wait time during which the sensor was at open 
circuit potential was employed at the start of the test 
sequence to ensure the mediator had dissolved off the 
overlayer. With higher galvanostatic currents there is a 
larger shift in potential starting at +0.4 V, with the shift 
seen at an earlier time for higher current, indicating the 
mediator has been depleted more quickly with higher 
galvanostatic current setting. A galvanostatic current of 
800 nA was selected.
The square wave voltammetry (SWV) response to 
MAMP in saliva buffer or saliva using galvanostatic oxi-
dation and the mediator overlayer is shown in Fig. 5. In 
saliva buffer, the main reduction peak at +0.38  V was 
reduced in the presence of MAMP (1800–1260 nA, 30 % 
reduction), and two new peaks were observed at +0.14 
and −0.06  V (717 and 1430  nA). The reduction peak 
heights were very significantly reduced in saliva com-
pared to saliva buffer, by approximately 85–95  % (peak 
heights at +0.34, +0.15 and −0.04  V were 205, 38 and 
88 nA in the presence of 5 μg/mL MAMP). The overall 
response time with the SWV procedure was 122  s. Ide-
ally the response time of the sensor would be in the range 
15–30  s, although a response time of less than 120  s 
would still be acceptable for a roadside test as it would 
be considerably faster than the existing roadside tests. 
Therefore the electrochemical procedure was optimized 
for speed of response.
In order to increase the speed of the SWV technique, 
the first part of the scan between +0.6 and +0.1 V was 
conducted at a higher scan rate compared to the second 
part of the scan between +0.1 V and −0.4 V. Both parts 
of the scan were optimized for amplitude, step size and 
frequency. The third peak height is independent of fre-
quency (Additional file 2), therefore a faster scan rate can 
be used for the first part of the scan without any adverse 
effect on the 3rd peak height.
Fig. 4 Varying the current during the galvanostatic oxidation step. 
The overlayer was treated with 0.12 mg/mL of OX1006 in 0.4 M 
sodium carbonate buffer (pH 10.8), containing 0.23 M NaCl and 0.1 % 
TX‑100. The procedure consisted of a 10 s wait time after application 
of 7 μL of saliva, followed by galvanostatic oxidation at 300, 800, 1200, 
1500 or 3000 nA for 30 s
Fig. 5 SWV response to MAMP in a saliva buffer or b saliva. The 
MAMP concentration was 0 μg/mL (solid line) or 5 μg/mL (dashed 
line). The overlayer was treated with 1.0 mg/mL of OX1006 in 0.4 M 
sodium carbonate buffer (pH 10.8), containing 1.0 M NaCl and 0.1 % 
TX‑100. The SWV procedure consisted of a 10 s wait time after appli‑
cation of 7 μL of sample, then (1) galvanostatic oxidation at 800 nA 
for 30 s, (2) SWV with start voltage +0.6 V, stop voltage −0.4 V, 4.25 Hz 
frequency, 2.85 mV step potential and 50 mV amplitude
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The split SWV responses to MAMP in saliva buffer 
and saliva are shown in Fig.  6, using frequencies of 20 
and 4.25  Hz for the first and second parts of the scan. 
The new peak in response to MAMP is clearly observed 
at −0.06 V for saliva buffer and −0.04 V for saliva. The 
overall response time is 55  s. The calibration plot for 
response to MAMP in a saliva sample using the third 
peak of the optimized split SWV technique is shown 
in Fig.  7. Good linearity of response to MAMP was 
obtained (R2 0.9877). The lower limit of detection was 
400 ng/mL (0 ng/mL response +3 SD) which is consid-
erably higher than that required for a commercial device 
(<10 ng/mL).
The LOD compares favourably with that obtained using 
indirect electrochemistry with 1,2-naphthoquinone-
4-sulfonate [16], and it is considerably higher than the 
LODs obtained using direct electrochemical methods 
[13–15], although all these methods use aqueous solution 
and not undiluted saliva. Use of microelectrodes should 
provide greater sensitivity of response, since increased 
mass transport of MAMP to the electrode should result 
in increased peak heights i.e. higher nA per ng/mL 
MAMP. However this would require reproducible screen 
printed microelectrodes and development of a suitable 
manufacturing methodology was beyond the time and 
budgetary restraints of this work.
The response to MAMP and amphetamine in saliva 
using the split SWV technique showed a new peak 
formed in response to MAMP at −0.04  V, and no new 
peak observed in response to amphetamine (Additional 
file 3). This demonstrates the selectivity of the mediator 
to secondary amines over primary amines.
Variation in response with different donor saliva samples
The response to saliva obtained from 10 donors is 
shown in Fig.  8. There is considerable variation in 1st 
and 3rd peak heights, and to a lesser extent the 2nd 
peak height, between the donors. At 0  μg/mL MAMP, 
the average peak heights range from 95 to 1878  nA 
for the 1st peak, 1523–2882  nA for the 2nd peak and 
0–6 nA for the 3rd peak. At 1 μg/mL MAMP, the aver-
age peak heights range from 129 to 1578 nA for the 1st 
peak, 1813–2573  nA for the 2nd peak and 0–113  nA 
for the 3rd peak. The individual donor samples can give 
very different responses. For example, while the major-
ity of the donor samples do not show a decrease in 1st 
and 2nd peak heights in response to MAMP, donors 6 
and 10 do show a decrease in 1st and 2nd peak heights 
in response to MAMP (donor 6 gave 90 and 37  % 
decrease and donor 10 gave 59 and 30 % in 1st and 2nd 
peak heights, for response to 0 and 1  μg/mL MAMP). 
However for the 3rd peak, donor 6 gave no response 
to MAMP, whereas for donor 10 the 3rd peak height 
increased from 2.4 to 18  nA for 0–1  μg/mL MAMP. It 
can also be observed that only the samples from donors 
2 and 8 show an increase in the 3rd peak height in 
Fig. 6 Split SWV response to MAMP in a saliva buffer or b saliva. The 
MAMP concentrations were 0 (solid line) or 5 μg/mL (dashed line). The 
overlayer was treated with 1.0 mg/mL of OX1006 in 0.4 M sodium 
carbonate buffer (pH 10.8), containing 1.0 M NaCl and 0.1 % TX‑100. 
The SWV procedure consisted of a 10 s wait time after application of 
7 μL of sample, then (1) galvanostatic oxidation at 800 nA for 30 s; (2) 
SWV‑1 with start voltage +0.6 V, stop voltage +0.1 V, 20 Hz frequency, 
10 mV step potential and 50 mV amplitude; (3) SWV‑2 with start 
voltage +0.1 V, stop voltage −0.4 V, 4.25 Hz frequency, 10 mV step 
potential and 100 mV amplitude
Fig. 7 Calibration plot for response to MAMP in saliva obtained from 
a single donor, using the 3rd peak height obtained with the split 
SWV technique. Each sample was tested with 12 sensors. Error bars 
are 1 SD. The overlayer treatment and electrochemical procedure are 
described in Fig. 6
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response to 100  ng/mL MAMP (donor 2, 6.1–13.5  nA 
and donor 8, 4.3–28.9 nA for response to 0 and 100 ng/
mL MAMP).
To further investigate the effect of donor variation in 
saliva on response, saliva from two donors was centrifu-
gally filtered using filters with cut-offs of 3, 10, 30 and 
100 kDa. The results are shown in Fig. 9. There was a sig-
nificant increase in the 2nd peak height and also in the 
3rd MAMP peak height for 100 kDa filtered saliva com-
pared to unfiltered saliva; with 1 μg/mL MAMP, the peak 
heights increase from 218 to 629 nA (donor 1, 2nd peak), 
and 15–142  nA (donor 1, 3rd peak), and from 329 to 
539 nA (donor 2, 2nd peak) and 88–285 nA (donor 2, 3rd 
peak). This indicates high molecular weight species such 
as proteins and mucin have a significant negative impact 
on the peak height. For donor 1, the 1st peak is not pre-
sent except for the 3 kDa filtered sample, while for donor 
2 the 1st peak was not present for the unfiltered samples, 
but was present for the filtered samples.
The response to MAMP increased with decreasing 
molecular weight cut-off of the filter e.g. for donor 1, the 
3rd peak heights in response to 1  μg/mL MAMP were 
15, 142 and 353 nA for unfiltered saliva, 100 and 3 kDa 
filters. However there is still considerable donor varia-
tion in response with the filtrate from the 3  kDa filter 
(the 3rd peak heights for donors 1 and 2 were 353 and 
Fig. 8 Donor variation in response to MAMP in saliva from 10 donors. a 1st and 2nd peak heights and b 3rd peak height. The MAMP concentrations 
were 0, 0.1, 0.25 and 1 μg/mL. Each sample was tested with 6 sensors. Error bars are 1 SD. The overlayer treatment and SWV procedure are described 
in Fig. 6
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512 nA respectively). While this filter will have removed 
larger proteins and mucins, some small proteins and 
protein fragments will remain, which may compete for 
adsorption sites on the electrode surface with the medi-
ator MAMP adduct. In addition, the filtrate will contain 
endogenous amines which may react with the mediator.
The effect of the saliva components mucin and 
lysozyme on response are shown in Table  1. Addition 
of mucin had little effect, whereas addition of lysozyme 
resulted in significant reduction in peak heights, demon-
strating the adverse effect of saliva proteins on response.
Experimental
(+)-Methamphetamine hydrochloride (M8750), 
d-amphetamine sulphate (A5880), human recombinant 
lysozyme (L1667) and mucin from bovine submaxil-
lary glands (M3895) were obtained from Sigma-Aldrich 
Co. Ltd (Poole, UK). The mediators were synthesized by 
Peakdale Molecular (High Peak, UK). All other chemicals 
were purchased from Sigma-Aldrich Co. Ltd. All chemi-
cals were used as received without further purification. 
All solutions were prepared using deionized water with 
resistivity no less than 18.2 MΩ cm.
Fig. 9 Response to MAMP in saliva from two donors, in unfiltered saliva and saliva filtrate. a 1st and 2nd peak heights and b 3rd peak height. Saliva 
filtrate was collected using centrifugal filters with 3, 10, 30 or 100 kDa cut‑offs. The MAMP concentrations were 0 or 1 μg/mL. Each sample was 
tested with 6 sensors. Error bars are 1 SD. The overlayer treatment and SWV procedure is described in Fig. 6, except the galvanostatic current was 
700 nA
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Screen printed electrodes were fabricated in house with 
appropriate stencil designs using a DEK Horizon printing 
machine (DEK, Weymouth, UK). Successive layers of car-
bon-graphite ink (C2120403D1, modified in house by the 
addition of 0.1  % TX-100), dielectric ink (D2070423P5) 
and Ag/AgCl ink (60:40, C2030812P3) obtained from 
Gwent Electronic Materials Ltd. (Pontypool, UK) were 
printed onto a polyester substrate. The layers were 
cured using a tunnel drier at 70  °C (Natgraph, Notting-
ham, UK). The reproducibility of response of a sample 
of sensors from each print batch was determined using 
square wave voltammetry (SWV) with 1 mM OX1006 in 
0.4 M sodium carbonate buffer (pH 10.8), 0.23 M NaCl, 
0.0018  % TX-100. The SWV settings were as follows: 
start potential +0.6  V, stop potential −0.5  V, frequency 
10  Hz, amplitude 0.05  V and step size 0.00285  V. Each 
sensor batch comprised 15 sheets with 4 rows of 48 sen-
sors per sheet. A sample of 12 sensors from the second 
sheet of each batch were tested for SWV response to 
OX1006, and the responses were characterized for peak 
position and peak height. The %CVs were typically in 
the range 0.5–1.7 and 3–5 % for peak position and peak 
height respectively.
Voltammetric measurements were performed using 
either a MultiAutolab M101 or a μ-Autolab III potentio-
stat (Eco Chemie). The screen printed sensors were used 
as a two electrode system, with a combined counter/ref-
erence electrode (Ag/AgCl ink).
The overlayer material was composed of abaca and 
cellulosic fibres (75 %) in a polypropylene thermoplas-
tic matrix (25  %), dry weight 16.5  g/m2 (CD020010, 
Ahlstrom) in reel format (1  cm wide) was obtained 
from Ahlstrom (Duns, UK). The overlayer was coated 
with OX1006 as follows: 1  mg/mL OX1006 was pre-
pared in 0.4  M sodium carbonate buffer solution (pH 
10.8) containing 1  M NaCl and 0.1  % Triton X-100. 
The solution was dispensed onto the membrane at a 
loading of 0.1–1 mg/mL and dried at 40 °C. The dried 
overlayer was heat soldered to each sensor along the 
edges.
Saliva buffer, which mimics real saliva except for the 
absence of proteins, consisted of 27.5 mM sodium chlo-
ride, 6.3 mM ammonium chloride, 4.9 mM sodium phos-
phate (monobasic), 2.9 mM potassium chloride, 1.1 mM 
sodium citrate (anhydrous), 0.02  mM magnesium 
chloride (anhydrous), 0.27  mM sodium carbonate and 
0.2 mM calcium chloride.
Each saliva sample was collected immediately before 
use by spitting into a pot. Saliva samples containing 
MAMP were prepared by dissolving MAMP directly into 
the saliva sample at 1 mg/mL. Saliva samples containing 
lower MAMP concentrations were obtained by dilution 
of the 1 mg/mL sample with neat saliva.
Centrifugal filtration of saliva was performed using 
Amicon Ultra 0.5  mL centrifugal filters with molecular 
cut-off weights of 100, 30, 10, and 3  kDa. The samples 
were centrifuged at 14,000g for 10 min. The filters were 
weighed before and after centrifugation and deionised 
water was added to each filtrate to adjust for volume lost.
Conclusions
The detection of 400  ng/mL MAMP in undiluted saliva 
has been reported using mediated disposable screen 
printed sensors with a response time of 55 s. While the 
response time is significantly faster than existing lateral 
flow immunodiagnostic tests, the limit of detection of the 
sensors is considerably higher (400  ng/mL compared to 
10 ng/mL) and is too high to be acceptable as a screen-
ing test. The precision of the sensor response is adversely 
affected by saliva proteins and further development of the 
sensor is required to overcome these effects and obtain 
a commercially viable sensor. Saliva samples are notori-
ously variable in terms of composition and viscosity, even 
within the same donor sample collected over a short 
period of time, and it is probable that an on-strip dilu-
tion of the sample would decrease adverse effects arising 
Table 1 Response to saliva buffer containing added protein
(A) No addition and with the addition of (B) 0.021 mg/mL mucin; (C) 0.3 mg/mL lysozyme and 0.021 mg/mL mucin; and (D) 3 mg/mL lysozyme and 0.021 mg/mL 
mucin. The overlayer was treated with 0.2 mg/mL of OX1006 in 0.4 M sodium carbonate buffer (pH 10.8), containing 0.23 M NaCl and 0.1 % TX-100. Each sample was 
tested with 6 sensors. The SWV procedure is described in Fig. 6
Average peak height/nA (±1 SD) % Decrease in peak height
1st peak (at +0.40 V) 2nd peak (at +0.25 V) 3rd peak (at −0.06 V) 1st peak 2nd peak 3rd peak
SSB 2865 ± 1369 3257 ± 1939 436 ± 30
SSB + 0.021 mg/mL mucin 2665 ± 728 2581 ± 893 481 ± 59 −7.0 −20.8 10.4
SSB + 0.021 mg/mL mucin + 0.3 mg/mL 
lysozyme
1952 ± 1009 1781 ± 1018 382 ± 70 −26.7 −31.0 −20.5
SSB + 0.021 mg/mL mucin + 3.0 mg/mL 
lysozyme
985 ± 275 717 ± 233 54 ± 29 −49.5 −59.7 −85.8
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from sample variability and viscosity, however this would 
require controlled sample dilution. It would also require 
greater sensitivity of response which may be achieved by 
the use of microelectrodes and this is a route that should 
be investigated further. In conclusion, development of a 
disposable roadside test for the rapid determination of 
methamphetamine in undiluted saliva is challenging, and 
requires significant further effort.
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